| [1] | Rinaldo-Matthis A, Haeggstr？m JZ (2010) Structures and mechanisms of enzymes in the leukotriene cascade. Biochimie 92: 676–681.
|
| [2] | B？ck M, Bu D-x, Br？nstr？m R, Sheikine Y, Yan Z-Q, et al. (2005) Leukotriene B4 signaling through NF-κB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proceedings of the National Academy of Sciences of the United States of America 102: 17501–17506.
|
| [3] | Barnes PJ (2002) New treatments for copd. Nat Rev Drug Discov 1: 437–446.
|
| [4] | Chen X-S, Shelter JR, Johnson EN, Funk CD (1994) Role of leukotrienes revealed by targeted disruption of the 5-lipoxygenase gene. Nature 372: 179–182.
|
| [5] | Drazen JM (1997) Pharmacology of Leukotriene Receptor Antagonists and 5-Lipoxygenase Inhibitors in the Management of Asthma. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17: 22S–30S.
|
| [6] | Gompertz S, Stockley RA (2002) A Randomized, Placebo-Controlled Trial of a Leukotriene Synthesis Inhibitor in Patients With COPD*. Chest 122: 289–294.
|
| [7] | Griffiths RJ, Pettipher ER, Koch K, Farrell CA, Breslow R, et al. (1995) Leukotriene B4 plays a critical role in the progression of collagen-induced arthritis. Proceedings of the National Academy of Sciences 92: 517–521.
|
| [8] | Henderson WR (1994) The Role of Leukotrienes in Inflammation. Annals of Internal Medicine 121: 684–697.
|
| [9] | Iversen L, Kragballe K, Ziboh VA (1997) Significance of Leukotriene-A4 Hydrolase in the Pathogenesis of Psoriasis. Skin Pharmacology and Physiology 10: 169–177.
|
| [10] | Peters-Golden M, Henderson WR (2007) Leukotrienes. New England Journal of Medicine 357: 1841–1854.
|
| [11] | Rao NL, Dunford PJ, Xue X, Jiang X, Lundeen KA, et al. (2007) Anti-Inflammatory Activity of a Potent, Selective Leukotriene A4 Hydrolase Inhibitor in Comparison with the 5-Lipoxygenase Inhibitor Zileuton. Journal of Pharmacology and Experimental Therapeutics 321: 1154–1160.
|
| [12] | Sharon P, Stenson WF (1984) Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 86: 453–460.
|
| [13] | Tsuji F, Oki K, Fujisawa K, Okahara A, Horiuchi M, et al. (1998) Involvement of leukotriene B4 in arthritis models. Life Sciences 64: PL51–PL56.
|
| [14] | Rudberg PC, Tholander F, Thunnissen MMGM, Haeggstr？m JZ (2002) Leukotriene A4Hydrolase/Aminopeptidase. Journal of Biological Chemistry 277: 1398–1404.
|
| [15] | Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, et al. (1993) 5-Lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase. European Journal of Biochemistry 215: 105–111.
|
| [16] | Dixon RAF, Diehl RE, Opas E, Rands E, Vickers PJ, et al. (1990) Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 343: 282–284.
|
| [17] | Kennedy BP, Diehl RE, Boie Y, Adam M, Dixon RA (1991) Gene characterization and promoter analysis of the human 5-lipoxygenase-activating protein (FLAP). Journal of Biological Chemistry 266: 8511–8516.
|
| [18] | Mancini JA, Abramovitz M, Cox ME, Wong E, Charleson S, et al. (1993) 5-lipoxygenase-activating protein is an arachidonate binding protein. FEBS Letters 318: 277–281.
|
| [19] | Rouzer CA, Matsumoto T, Samuelsson B (1986) Single protein from human leukocytes possesses 5-lipoxygenase and leukotriene A4 synthase activities. Proceedings of the National Academy of Sciences 83: 857–861.
|
| [20] | Shimizu T, Izumi T, Seyama Y, Tadokoro K, R？dmark O, et al. (1986) Characterization of leukotriene A4 synthase from murine mast cells: evidence for its identity to arachidonate 5-lipoxygenase. Proceedings of the National Academy of Sciences 83: 4175–4179.
|
| [21] | Thangapandian S, John S, Sakkiah S, Lee KW (2011) Pharmacophore-based virtual screening and Bayesian model for the identification of potential human leukotriene A4 hydrolase inhibitors. European Journal of Medicinal Chemistry 46: 1593–1603.
|
| [22] | Molina DM, Wetterholm A, Kohl A, McCarthy AA, Niegowski D, et al. (2007) Structural basis for synthesis of inflammatory mediators by human leukotriene C4 synthase. Nature 448: 613–616.
|
| [23] | Samuelsson B, Dahlen S, Lindgren J, Rouzer C, Serhan C (1987) Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237: 1171–1176.
|
| [24] | Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, et al. (1999) Lipoxygenase Inhibitors as Potential Cancer Chemopreventives. Cancer Epidemiology Biomarkers & Prevention 8: 467–483.
|
| [25] | Thangapandian S, John S, Arooj M, Lee KW (2012) Molecular Dynamics Simulation Study and Hybrid Pharmacophore Model Development in Human LTA4H Inhibitor Design. PLoS ONE 7: e34593.
|
| [26] | Haeggstr？m JZ, Kull F, Rudberg PC, Tholander F, Thunnissen MMGM (2002) Leukotriene A4 hydrolase. Prostaglandins & Other Lipid Mediators 68–69: 495–510.
|
| [27] | Rudberg PC, Tholander F, Andberg M, Thunnissen MMGM, Haeggstr？m JZ (2004) Leukotriene A4 Hydrolase. Journal of Biological Chemistry 279: 27376–27382.
|
| [28] | Jiang X, Zhou L, Wu Y, Wei D, Sun C, et al. (2010) Modulating the Substrate Specificity of LTA4H Aminopeptidase by Using Chemical Compounds and Small-Molecule-Guided Mutagenesis. ChemBioChem 11: 1120–1128.
|
| [29] | Haeggstr？m JZ, Wetterholm A, Shapiro R, Vallee BL, Samuelsson B (1990) Leukotriene A4 hydrolase: A zinc metalloenzyme. Biochemical and Biophysical Research Communications 172: 965–970.
|
| [30] | Malfroy B, Kado-Fong H, Gros C, Giros B, Schwartz J-C, et al. (1989) Molecular cloning and amino acid sequence of rat kidney aminopeptidase M: A member of a super family of zinc-metallohydrolases. Biochemical and Biophysical Research Communications 161: 236–241.
|
| [31] | Minami M, Ohishi N, Mutoh H, Izumi T, Bito H, et al. (1990) Leukotriene A4 hydrolase is a zinc-containing aminopeptidase. Biochemical and Biophysical Research Communications 173: 620–626.
|
| [32] | Vallee BL, Auld DS (1990) Zinc coordination, function, and structure of zinc enzymes and other proteins. Biochemistry 29: 5647–5659.
|
| [33] | Blomster M, Wetterholm A, Mueller MJ, Haeggstr？m JZ (1995) Evidence for a Catalytic Role of Tyrosine 383 in the Peptidase Reaction of Leukotriene A4 Hydrolase. European Journal of Biochemistry 231: 528–534.
|
| [34] | Haeggstr？m JZ (2004) Leukotriene A4 Hydrolase/Aminopeptidase, the Gatekeeper of Chemotactic Leukotriene B4 Biosynthesis. Journal of Biological Chemistry 279: 50639–50642.
|
| [35] | Orning L, Gierse JK, Fitzpatrick FA (1994) The bifunctional enzyme leukotriene-A4 hydrolase is an arginine aminopeptidase of high efficiency and specificity. Journal of Biological Chemistry 269: 11269–11273.
|
| [36] | Wetterholm A, Medina JF, R？dmark O, Shapiro R, Haeggstr？m JZ, et al. (1992) Leukotriene A4 hydrolase: abrogation of the peptidase activity by mutation of glutamic acid-296. Proceedings of the National Academy of Sciences 89: 9141–9145.
|
| [37] | Davies DR, Mamat B, Magnusson OT, Christensen J, Haraldsson MH, et al. (2009) Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography？. Journal of Medicinal Chemistry 52: 4694–4715.
|
| [38] | Kirkland TA, Adler M, Bauman JG, Chen M, Haeggstr？m JZ, et al. (2008) Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A4 hydrolase. Bioorganic & Medicinal Chemistry 16: 4963–4983.
|
| [39] | Sandanayaka V, Mamat B, Mishra RK, Winger J, Krohn M, et al. (2009) Discovery of 4- [(2S)-2-{[4-(4-Chlorophenoxy)phenoxy] methyl}-1-pyrrolidinyl] butanoic Acid (DG-051) as a Novel Leukotriene A4 Hydrolase Inhibitor of Leukotriene B4 Biosynthesis. Journal of Medicinal Chemistry 53: 573–585.
|
| [40] | Tholander F, Muroya A, Roques B-P, Fournié-Zaluski M-C, Thunnissen MMGM, et al. (2008) Structure-Based Dissection of the Active Site Chemistry of Leukotriene A4 Hydrolase: Implications for M1 Aminopeptidases and Inhibitor Design. Chemistry & Biology 15: 920–929.
|
| [41] | Thunnissen MMGM, Andersson B, Samuelsson B, Wong C-H, Haeggstrom JZ (2002) Crystal structures of leukotriene A4 hydrolase in complex with captopril and two competitive tight-binding inhibitors. The FASEB Journal 16: 1648–1650.
|
| [42] | Thunnissen MMGM, Nordlund P, Haeggstrom JZ (2001) Crystal structure of human leukotriene A4 hydrolase, a bifunctional enzyme in inflammation. Nat Struct Mol Biol 8: 131–135.
|
| [43] | Rudberg PC, Tholander F, Thunnissen MMGM, Samuelsson B, Haeggstr？m JZ (2002) Leukotriene A4 hydrolase: Selective abrogation of leukotriene B4 formation by mutation of aspartic acid 375. Proceedings of the National Academy of Sciences 99: 4215–4220.
|
| [44] | Mueller MJ, Wetterholm A, Blomster M, J？rnvall H, Samuelsson B, et al. (1995) Leukotriene A4 hydrolase: mapping of a henicosapeptide involved in mechanism-based inactivation. Proceedings of the National Academy of Sciences 92: 8383–8387.
|
| [45] | Vazeux G, Iturrioz X, Corvol P, Llorens-Cortes C (1998) A glutamate residue contributes to the exopeptidase specificity in aminopeptidase A. Biochemical Journal 334: 407–413.
|
| [46] | Maycock AL, Anderson MS, DeSousa DM, Kuehl FA Jr (1982) Leukotriene A4: preparation and enzymatic conversion in a cell-free system to leukotriene B4. J Biol Chem 257: 13911–13914.
|
| [47] | Chou K-C (2004) Review: Structural bioinformatics and its impact to biomedical science. Current Medicinal Chemistry 11: 2105–2134.
|
| [48] | Chou K-C, Watenpaugh KD, Heinrikson RL (1999) A Model of the Complex between Cyclin-Dependent Kinase 5 and the Activation Domain of Neuronal Cdk5 Activator. Biochemical and Biophysical Research Communications 259: 420–428.
|
| [49] | Zhang J, Luan C-H, Chou K-C, Johnson GVW (2002) Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling. Proteins: Structure, Function, and Bioinformatics 48: 447–453.
|
| [50] | Chou K-C, Wei D-Q, Zhong W-Z (2003) Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS. Biochemical and Biophysical Research Communications 308: 148–151.
|
| [51] | Du Q-S, Sun H, Chou K-C (2007) Inhibitor design for SARS coronavirus main protease based on “distorted key theory” Medicinal Chemistry 3: 1–6.
|
| [52] | Housaindokht MR, Bozorgmehr MR, Bahrololoom M (2008) Analysis of ligand binding to proteins using molecular dynamics simulations. Journal of Theoretical Biology 254: 294–300.
|
| [53] | Huang R-B, Du Q-S, Wang C-H, Chou K-C (2008) An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus. Biochemical and Biophysical Research Communications 377: 1243–1247.
|
| [54] | Wang S-Q, Du Q-S, Chou K-C (2007) Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases. Biochemical and Biophysical Research Communications 354: 634–640.
|
| [55] | Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein–ligand docking using GOLD. Proteins: Structure, Function, and Bioinformatics 52: 609–623.
|
| [56] | Cheng F, Wang Q, Chen M, Quiocho FA, Ma J (2008) Molecular docking study of the interactions between the thioesterase domain of human fatty acid synthase and its ligands. Proteins: Structure, Function, and Bioinformatics 70: 1228–1234.
|
| [57] | Thomsen R, Christensen MH (2006) MolDock: A New Technique for High-Accuracy Molecular Docking. Journal of Medicinal Chemistry 49: 3315–3321.
|
| [58] | Chou KC (1984) Biological functions of low-frequency vibrations (phonons). III. Helical structures and microenvironment. Biophysical Journal 45: 881–889.
|
| [59] | Wang J-F, Chou K-C (2009) Insight into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochemical and Biophysical Research Communications 390: 608–612.
|
| [60] | Chou K-C (1989) Low-frequency resonance and cooperativity of hemoglobin. Trends in Biochemical Sciences 14: 212.
|
| [61] | Chou K-C (1984) The biological functions of low-frequency vibrations (phonons): 4. Resonance effects and allosteric transition. Biophysical Chemistry 20: 61–71.
|
| [62] | Chou K-C (1987) The biological functions of low-frequency vibrations (phonons). VI. A possible dynamic mechanism of allosteric transition in antibody molecules. Biopolymers 26: 285–295.
|
| [63] | Chou K-C, Mao B (1988) Collective motion in DNA and its role in drug intercalation. Biopolymers 27: 1795–1815.
|
| [64] | Chou K-C, Zhang C-T, Maggiora GM (1994) Solitary wave dynamics as a mechanism for explaining the internal motion during microtubule growth. Biopolymers 34: 143–153.
|
| [65] | Chou K-C (1988) Low-frequency collective motion in biomacromolecules and its biological functions. Biophysical Chemistry 30: 3–48.
|
| [66] | Hess B, Kutzner C, van der Spoel D, Lindahl E (2008) GROMACS 4: Algorithms for Highly Efficient, Load-Balanced, and Scalable Molecular Simulation. Journal of Chemical Theory and Computation 4: 435–447.
|
| [67] | Van Der Spoel D, Lindahl E, Hess B, Groenhof G, Mark AE, et al. (2005) GROMACS: Fast, flexible, and free. Journal of Computational Chemistry 26: 1701–1718.
|
